Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

117 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Programmed Death Ligand 1 (PD-L1) Expression in Primary Angiosarcoma.
Botti G, Scognamiglio G, Marra L, Pizzolorusso A, Di Bonito M, De Cecio R, Cantile M, De Chiara A. Botti G, et al. Among authors: di bonito m. J Cancer. 2017 Sep 15;8(16):3166-3172. doi: 10.7150/jca.19060. eCollection 2017. J Cancer. 2017. PMID: 29158788 Free PMC article.
Biweekly docetaxel-irinotecan with filgrastim support in pretreated breast and non-small-cell lung cancer patients. A phase I study.
Frasci G, Comella P, Thomas R, Di Bonito M, Lapenta L, Capasso I, Botti G, Vallone P, De Rosa V, D'Aiuto G, Comella G. Frasci G, et al. Among authors: di bonito m. Cancer Chemother Pharmacol. 2004 Jan;53(1):25-32. doi: 10.1007/s00280-003-0669-x. Epub 2003 Sep 26. Cancer Chemother Pharmacol. 2004. PMID: 14513281 Clinical Trial.
Weekly cisplatin, epirubicin, and paclitaxel with granulocyte colony-stimulating factor support vs triweekly epirubicin and paclitaxel in locally advanced breast cancer: final analysis of a sicog phase III study.
Frasci G, D'Aiuto G, Comella P, Thomas R, Botti G, Di Bonito M, De Rosa V, Iodice G, Rubulotta MR, Comella G; Southern Italy Cooperative Oncology Group (SICOG). Frasci G, et al. Among authors: di bonito m. Br J Cancer. 2006 Oct 23;95(8):1005-12. doi: 10.1038/sj.bjc.6603395. Br J Cancer. 2006. PMID: 17047649 Free PMC article. Clinical Trial.
Vinorelbine plus 3-weekly trastuzumab in metastatic breast cancer: a single-centre phase 2 trial.
De Maio E, Pacilio C, Gravina A, Morabito A, Di Rella F, Labonia V, Landi G, Nuzzo F, Rossi E, Silvestro P, Botti G, Di Bonito M, Curcio MP, Formichelli F, La Vecchia F, Staiano M, Maurea N, D'Aiuto G, D'Aiuto M, Thomas R, Signoriello G, Perrone F, de Matteis A. De Maio E, et al. Among authors: di rella f, di bonito m. BMC Cancer. 2007 Mar 20;7:50. doi: 10.1186/1471-2407-7-50. BMC Cancer. 2007. PMID: 17374151 Free PMC article. Clinical Trial.
Retrospective evaluation of clinical outcomes in patients with HER2-positive advanced breast cancer progressing on trastuzumab-based therapy in the pre-lapatinib era.
Montemurro F, Redana S, Viale G, Sanna G, Donadio M, Valabrega G, del Curto B, Bottini A, Botti G, dei Tos AP, Jacomuzzi ME, Di Bonito M, Danese S, Clavarezza M, Kulka J, Di Palma S, Durando A, Sapino A, Aglietta M. Montemurro F, et al. Among authors: di bonito m, di palma s. Clin Breast Cancer. 2008 Oct;8(5):436-42. doi: 10.3816/CBC.2008.n.053. Clin Breast Cancer. 2008. PMID: 18952558
Effects on quality of life of weekly docetaxel-based chemotherapy in patients with locally advanced or metastatic breast cancer: results of a single-centre randomized phase 3 trial.
Nuzzo F, Morabito A, Gravina A, Di Rella F, Landi G, Pacilio C, Labonia V, Rossi E, De Maio E, Piccirillo MC, D'Aiuto G, Thomas R, Rinaldo M, Botti G, Di Bonito M, Di Maio M, Gallo C, Perrone F, de Matteis A. Nuzzo F, et al. Among authors: di rella f, di maio m, di bonito m. BMC Cancer. 2011 Feb 16;11:75. doi: 10.1186/1471-2407-11-75. BMC Cancer. 2011. PMID: 21324184 Free PMC article. Clinical Trial.
117 results